CN112638375A - 通过后细胞信号传导因子的调节来增加免疫活性 - Google Patents

通过后细胞信号传导因子的调节来增加免疫活性 Download PDF

Info

Publication number
CN112638375A
CN112638375A CN201980053471.XA CN201980053471A CN112638375A CN 112638375 A CN112638375 A CN 112638375A CN 201980053471 A CN201980053471 A CN 201980053471A CN 112638375 A CN112638375 A CN 112638375A
Authority
CN
China
Prior art keywords
cell
cells
activity
agent
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980053471.XA
Other languages
English (en)
Chinese (zh)
Inventor
A·M·巴索蒂
A·M·坎特莱
J·帕克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flagship Entrepreneurship And Innovation Co 5
Flagship Pioneering Innovations V Inc
Original Assignee
Flagship Entrepreneurship And Innovation Co 5
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Entrepreneurship And Innovation Co 5 filed Critical Flagship Entrepreneurship And Innovation Co 5
Publication of CN112638375A publication Critical patent/CN112638375A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
CN201980053471.XA 2018-06-15 2019-06-14 通过后细胞信号传导因子的调节来增加免疫活性 Pending CN112638375A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862685770P 2018-06-15 2018-06-15
US62/685,770 2018-06-15
US201862781819P 2018-12-19 2018-12-19
US62/781,819 2018-12-19
PCT/US2019/037350 WO2019241730A2 (fr) 2018-06-15 2019-06-14 Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires

Publications (1)

Publication Number Publication Date
CN112638375A true CN112638375A (zh) 2021-04-09

Family

ID=67138105

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980053471.XA Pending CN112638375A (zh) 2018-06-15 2019-06-14 通过后细胞信号传导因子的调节来增加免疫活性

Country Status (9)

Country Link
US (1) US20210251994A1 (fr)
EP (1) EP3806848A2 (fr)
JP (1) JP2021528393A (fr)
KR (1) KR20210035805A (fr)
CN (1) CN112638375A (fr)
AU (1) AU2019287765A1 (fr)
CA (1) CA3103629A1 (fr)
MA (1) MA52889A (fr)
WO (1) WO2019241730A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113421613A (zh) * 2021-06-08 2021-09-21 吴安华 一种基于铁死亡水平评价胶质母细胞瘤患者免疫治疗反应性的系统及分析方法
CN115804772A (zh) * 2022-11-16 2023-03-17 山东大学 一种铁死亡抑制剂在抗病毒感染中的应用
CN117625547A (zh) * 2022-08-25 2024-03-01 广州百吉生物制药有限公司 联合表达gpx4的新一代嵌合抗原受体及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3915585A1 (fr) * 2020-05-26 2021-12-01 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Combinaisons thérapeutiques comprenant des agonistes de la ferroptose pour le traitement de troubles prolifératifs
US11541116B1 (en) 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017120445A1 (fr) * 2016-01-07 2017-07-13 The Broad Institute, Inc. Composés et des méthodes pour augmenter l'infiltration tumorale par des cellules immunitaires

Family Cites Families (241)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR104E (fr)
US5843708A (en) 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
DE19939653A1 (de) 1999-08-13 2001-02-22 Thomas Huenig Verwendung CD28 spezifischer monoklonaler Antikörper zur Herstellung einer pharmazeutischen Zusammensetzung
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
WO2001024823A1 (fr) 1999-10-04 2001-04-12 Chiron Corporation Antagonistes de cd40 permettant de traiter le psoriasis
WO2001054732A1 (fr) 2000-01-27 2001-08-02 Genetics Institute, Llc. Anticorps contre ctla4 (cd152), conjugues comprenant lesdits anticorps, et leurs utilisations
JP2004505927A (ja) 2000-04-19 2004-02-26 タノックス　インコーポレイテッド 乾癬及び他の炎症性皮膚状態の治療用ｃｄ４０アンタゴニスト
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
ATE541860T1 (de) 2000-10-02 2012-02-15 Novartis Vaccines & Diagnostic Humane antikörper gegen cd40 zur therapie von b- zell tumoren
DE10050935A1 (de) 2000-10-11 2002-05-02 Tegenero Gmbh Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
WO2002032375A2 (fr) 2000-10-18 2002-04-25 Sloan-Kettering Institute For Cancer Research Utilisations d'anticorps monoclonal 8h9
WO2003075846A2 (fr) 2002-03-08 2003-09-18 Sloan-Kettering Institute For Cancer Research Utilisations d'anticorps 8h9 monoclonaux
US8414892B2 (en) 2000-10-18 2013-04-09 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US8501471B2 (en) 2000-10-18 2013-08-06 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US20020102264A1 (en) 2000-10-18 2002-08-01 Cheung Nai-Kong V. Uses of monoclonal antibody 8H9
AR031924A1 (es) 2000-12-14 2003-10-08 Fujisawa Pharmaceutical Co Anticuerpos anti-cd28 silenciados y el uso de estos
JP4066166B2 (ja) 2000-12-26 2008-03-26 アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル（アンセルム） 抗−ｃｄ２８抗体
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
EP2009027B1 (fr) 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anticorps monoclonal anti-CD40
WO2003029296A1 (fr) 2001-10-02 2003-04-10 Chiron Corporation Anticorps humains diriges contre le cd40
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
JP2005510570A (ja) 2001-11-26 2005-04-21 カイロン コーポレイション 多発性硬化症処置のためのアンタゴニスト抗ｃｄ４０モノクローナル抗体療法
US20080199471A1 (en) 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
DE10212108A1 (de) 2002-03-13 2003-10-02 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
DE60317677T2 (de) 2002-06-13 2008-10-30 Crucell Holland B.V. Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
DE10230223A1 (de) 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
US7052694B2 (en) 2002-07-16 2006-05-30 Mayo Foundation For Medical Education And Research Dendritic cell potentiation
US6693136B1 (en) 2002-07-26 2004-02-17 Abbott Laboratories Fluorenes and anthracenes that inhibit P2X3 and P2X2/3 containing receptors
AU2003259294A1 (en) 2002-07-30 2004-02-16 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
BRPI0410785A (pt) 2003-05-23 2006-06-20 Wyeth Corp molécula de ácido nucleico isolada, célula hospedeira, animal transgênico não humano, proteìna isolada, oligonucleotìdeo anti-sentido, molécula de sirna, anticorpo isolado, métodos de triagem quanto aos compostos de teste capazes de inibir, de intensificar ou imitar a interação do gitrl com o gitr, para diagnosticar doenças, para tratar um paciente em risco ou diagnosticado com uma doença, para induzir e para inibir a proliferação de uma população celular contendo células t efetoras, de bloquear a supressão e de supressão de uma população celular que inclua células t efetoras na presença de células t reguladoras cd4+cd25+, e para tratar uma doença, composição farmacêutica, e, adjuvante de vacina
US20090191213A9 (en) 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
EP1600164A3 (fr) 2003-09-22 2006-05-17 TeGenero AG Utilisation d'une substance liant le CD28 dans la production d'une composition pharmaceutique à effet dose-dépendant
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
DE602004028037D1 (de) 2003-11-04 2010-08-19 Novartis Vaccines & Diagnostic Verfahren zur behandlung von krebs mit expression des cd40-antigens
ATE516819T1 (de) 2003-11-04 2011-08-15 Novartis Vaccines & Diagnostic Verfahren zur behandlung von b-zell-bedingtem krebs
EP2243492A1 (fr) 2003-11-04 2010-10-27 Novartis Vaccines and Diagnostics, Inc. Utilisation d'anticorps monoclonaux antagonistes anti-CD40 pour le traitement de myélome multiple
SI1680141T1 (sl) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostic Postopki terapije za trdne tumorje, ki izražajo CD-40 celično-površinski antigen
EP1682177B8 (fr) 2003-11-04 2010-09-01 Novartis Vaccines and Diagnostics, Inc. Utilisation d'anticorps anti-cd40 antagonistes pour le traitement de la leucemie lymphocytique chronique
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
DE10352900A1 (de) 2003-11-11 2005-06-16 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
KR101223373B1 (ko) 2003-12-25 2013-01-16 교와 핫꼬 기린 가부시키가이샤 항 ｃｄ４０ 항체의 변이체
US20060099203A1 (en) 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
EP2287195B1 (fr) 2004-07-01 2019-05-15 Novo Nordisk A/S Anticorps contre le Pan-KIR2DL NK-recepteur et leur utilsation diagnostique at therapeutique
US20080057070A1 (en) 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
DE102004063494A1 (de) 2004-12-23 2006-07-13 Tegenero Ag Antikörper
PL1836225T3 (pl) 2005-01-06 2012-05-31 Novo Nordisk As Czynniki wiążące kir i sposoby ich stosowania
EP1835929B8 (fr) 2005-01-06 2016-07-27 Novo Nordisk A/S Procédés et traitements combinés anti-kir
US8551483B2 (en) 2005-01-06 2013-10-08 Innate Pharma S.A.S. Methods of treating viral infections by administering KIR2DL-binding antibodies
US20070161644A1 (en) 2005-01-25 2007-07-12 Stockwell Brent R Erastin analogs and uses thereof
BRPI0607306A2 (pt) 2005-01-25 2009-08-25 Prolexys Pharmaceuticals Inc derivados de quinoxalina como agentes anti-tumor
US8759490B2 (en) 2005-03-24 2014-06-24 Millennium Pharamaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
EP2384767B1 (fr) 2005-03-24 2016-03-09 Millennium Pharmaceuticals, Inc. Anticorps se liant à l'OV064 et leurs procédés d'utilisation
EP2343320B1 (fr) 2005-03-25 2017-10-25 GITR, Inc. Anticorps contre gitr et leur utilisations
US20060240006A1 (en) 2005-04-20 2006-10-26 Chishih Chu Novel antibody structures derived from human germline sequences
JP2008539271A (ja) 2005-04-27 2008-11-13 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション ｃｓＰＣＮＡイソ型抗体およびその使用
RU2406760C3 (ru) 2005-05-09 2017-11-28 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
US7585960B2 (en) 2005-05-11 2009-09-08 Theramab Gmbh Nucleic acids encoding superagonistic anti-CD28 antibodies
EP1894012A2 (fr) 2005-05-18 2008-03-05 Novartis AG Methodes de diagnostic et de traitement des maladies proliferatives mediees par la signalisation cd40
US8333970B2 (en) 2005-05-18 2012-12-18 Novartis Ag Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject having an inflammatory or autoimmune disease
KR100694508B1 (ko) 2005-05-24 2007-03-13 울산대학교 산학협력단 Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
US8303955B2 (en) 2005-05-26 2012-11-06 Seattle Genetics, Inc. Humanized anti-CD40 antibodies and their methods of use
CA3018525C (fr) 2005-07-01 2023-08-01 E. R. Squibb & Sons, L.L.C. Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
CA2627891A1 (fr) 2005-11-01 2007-05-10 Novartis Ag Utilisations d'anticorps anti-cd40
EP1945260B1 (fr) 2005-11-01 2012-10-24 Novartis AG Utilisations d'anticorps anti-cd40
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
CA2630483C (fr) 2005-12-08 2015-05-19 Medarex, Inc. Anticorps monoclonaux humains se fixant a l'o8e
BRPI0619586A2 (pt) 2005-12-09 2018-08-28 Seattle Genetics Inc método para o tratamento ou prevenção de um distúrbio associado com cd40
BRPI0620264A2 (pt) 2005-12-22 2011-11-08 Prolexys Pharmaceuticals Inc quinazolonas aril-substituìdas e sua utilização
TW200811185A (en) 2005-12-22 2008-03-01 Prolexys Pharmaceuticals Inc Fused pyrimidones and thiopyrimidones, and uses thereof
US20110008368A1 (en) 2006-01-13 2011-01-13 Board Of Regents, The University Of Texas System Methods of modulating the ox40 receptor to treat cancer
AU2007240507B2 (en) 2006-04-21 2013-07-18 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions
EP1854810A1 (fr) 2006-05-09 2007-11-14 PanGenetics B.V. Anticorps monoclonal anti CD40 humain déimmunisé et antagoniste dérivé de l'anticorps ch5D12
WO2007149476A2 (fr) 2006-06-19 2007-12-27 Trustees Of Columbia University In The City Of New York Déterminations de la mort cellulaire non apoptotique et leurs utilisations
KR100745488B1 (ko) 2006-07-04 2007-08-02 학교법인 울산공업학원 항-4-1ｂｂ 항체 및 화학 항암제를 포함하는 암 질환 예방및 치료용 약학 조성물
WO2008013987A2 (fr) 2006-07-27 2008-01-31 Prolexys Pharmaceuticals, Inc. Pipérazinylméthylquinazolinones et azépanylméthylquinazolinones à substitution n-alkyle
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
WO2008076560A2 (fr) 2006-11-15 2008-06-26 Medarex, Inc. Anticorps monoclonaux humains contre le btla et procédés d'utilisation
WO2008084106A1 (fr) 2007-01-11 2008-07-17 Novo Nordisk A/S Anticorps anti-kir, formulations et utilisations de celles-ci
EP2125893A2 (fr) 2007-01-23 2009-12-02 Xencor, Inc. Anticorps cd40 optimisés et leurs procédés d'utilisation
WO2008103470A2 (fr) * 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Composés létaux dépendants du signal de ras oncogénique
CN101687021B (zh) 2007-03-22 2013-04-17 斯隆-凯特琳癌症研究院 单克隆抗体8h9的应用
WO2008137915A2 (fr) 2007-05-07 2008-11-13 Medimmune, Llc Anticorps anti-icos et leur utilisation en traitement oncologique, de transplantation et maladie auto-immune
AU2008251800B2 (en) 2007-05-10 2014-07-10 Dogwood Pharmaceuticals, Inc. Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
KR20080107050A (ko) 2007-06-05 2008-12-10 울산대학교 산학협력단 항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
BRPI0812913B8 (pt) 2007-06-18 2021-05-25 Merck Sharp & Dohme anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
KR20100088621A (ko) 2007-11-09 2010-08-09 노파르티스 아게 항-ｃｄ40 항체의 용도
AR069747A1 (es) 2007-11-30 2010-02-17 Medarex Inc Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
EP3141265A1 (fr) 2007-12-04 2017-03-15 Alnylam Pharmaceuticals, Inc. Conjugués glucidiques utilisés comme agents d'administration pour des oligonucléotides
AU2009206506B2 (en) 2008-01-23 2013-01-10 Xencor, Inc. Optimized CD40 antibodies and methods of using the same
WO2009114335A2 (fr) 2008-03-12 2009-09-17 Merck & Co., Inc. Protéines de liaison avec pd-1
WO2009134389A2 (fr) 2008-05-01 2009-11-05 Gtc Biotherapeutics, Inc. Anticorps anti-cd137 en tant qu'agent dans le traitement d'états inflammatoires
WO2010001908A1 (fr) 2008-06-30 2010-01-07 協和発酵キリン株式会社 Anticorps anti-cd27
NZ596171A (en) 2008-07-16 2012-05-25 Baylor Res Inst Hiv vaccine based on targeting maximized gag and nef to dendritic cells
US20110097339A1 (en) 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
WO2010007376A2 (fr) 2008-07-18 2010-01-21 Domantis Limited Compositions monovalentes pour la liaison à cd28 et procédés d’utilisation
NZ590343A (en) 2008-07-18 2012-10-26 Bristol Myers Squibb Co Compositions monovalent for cd28 binding and methods of use
EP2342229A1 (fr) 2008-09-12 2011-07-13 ISIS Innovation Limited Anticorps spécifiques de pd-1 et leurs utilisations
WO2010029434A1 (fr) 2008-09-12 2010-03-18 Isis Innovation Limited Anticorps spécifiques de pd-1 et leurs utilisations
CA2738252C (fr) 2008-09-26 2018-05-01 Dana-Farber Cancer Institute, Inc. Anticorps anti-pd-1, pd-l1, et pd-l2 humains et leurs utilisations
WO2010042433A1 (fr) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combinaison d'anticorps cd137 et d'anticorps ctla-4 pour le traitement de maladies prolifératives
WO2010065939A1 (fr) 2008-12-05 2010-06-10 Indiana University Research & Technology Corporation Traitement combiné pour améliorer la cytotoxicité induite par les cellules nk
NZ717213A (en) 2008-12-09 2017-10-27 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010082912A1 (fr) 2009-01-15 2010-07-22 Avalon Pharmaceuticals Dérivés de composés aromatiques à noyaux multiples et utilisations comme agents anti-tumoraux
UA107341C2 (uk) 2009-02-17 2014-12-25 Ucb Pharma Sa Молекули антитіл, що мають специфічність до людського ox40
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
DK3138854T3 (da) 2009-03-10 2022-04-11 Baylor Res Institute Antistoffer mod CD40
CA3032548C (fr) 2009-03-10 2023-05-09 Baylor Research Institute Anticorps anti-cd40 et utilisations de ceux-ci
EP2417984B1 (fr) 2009-04-10 2016-03-30 Kyowa Hakko Kirin Co., Ltd. Procédé pour le traitement d'une tumeur sanguine utilisant un anticorps anti-tim-3
HUE028537T2 (en) 2009-04-20 2016-12-28 Kyowa Hakko Kirin Co Ltd Built-in amino acid mutation IgG2 antibody
WO2010132389A2 (fr) 2009-05-14 2010-11-18 University Of Maryland, Baltimore Procédés de traitement de cancers et de maladies associées à l'expression de 4-1bb (cd137)
US8563694B2 (en) 2009-07-31 2013-10-22 Medarex, Inc. Fully human antibodies to BTLA
PT3023438T (pt) 2009-09-03 2020-05-08 Merck Sharp & Dohme Anticorpos anti-gitr
WO2011031063A2 (fr) 2009-09-09 2011-03-17 울산대학교 산학협력단 Composition de prévention ou de traitement de troubles métaboliques contenant l'anticorps anti-4-1bb
PL3279215T3 (pl) 2009-11-24 2020-06-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
CA2781311C (fr) 2009-12-07 2019-03-12 The Board Of Trustees Of The Leland Stanford Junior University Methodes d'amplification d'un traitement a base d'anticorps anticancereux
CN102918059A (zh) 2009-12-29 2013-02-06 协和发酵麒麟株式会社 抗cd27抗体
WO2011091078A2 (fr) 2010-01-19 2011-07-28 Xencor, Inc. Variants d'anticorps possédant une activité complémentaire accrue
KR20110085038A (ko) 2010-01-19 2011-07-27 울산대학교 산학협력단 항 ｃｄ137-항체 및 독소 결합물을 이용한 ｃｄ137 양성세포의 제거방법
PL2536764T3 (pl) 2010-02-18 2018-12-31 Ose Immunotherapeutics Humanizowane przeciwciała anty-CD28
NZ602161A (en) 2010-03-04 2014-12-24 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
PT3178851T (pt) 2010-03-31 2020-07-17 Boehringer Ingelheim Int Anticorpos anti-cd40
US9028830B2 (en) 2010-04-08 2015-05-12 JN Biosciences, LLC Antibodies to CD122
US20120213771A1 (en) 2010-04-13 2012-08-23 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
EP2558498B1 (fr) 2010-04-13 2016-10-12 Celldex Therapeutics, Inc. Anticorps qui se lient au cd27 humain et utilisations de ceux-ci
ES2682078T3 (es) 2010-06-11 2018-09-18 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-TIM-3
AU2011275749C1 (en) 2010-07-09 2015-09-17 Aduro Biotech Holdings, Europe B.V. Agonistic antibody to CD27
SG187945A1 (en) 2010-08-23 2013-03-28 Univ Texas Anti-ox40 antibodies and methods of using the same
ES2699648T3 (es) 2010-09-09 2019-02-12 Pfizer Moléculas de unión a 4-1BB
JP2013541334A (ja) 2010-09-15 2013-11-14 アルニラム ファーマスーティカルズ インコーポレイテッド 修飾されたｉＲＮＡ剤
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
TWI664191B (zh) 2010-11-22 2019-07-01 天賜製藥公司 Ｎｋ細胞調節治療及治療血液惡性疾病之方法
WO2012075111A1 (fr) 2010-11-30 2012-06-07 Novartis Ag Utilisation d'anticorps anti-cd40 en thérapie combinée contre des cancers associés aux cellules b
AU2011349502B2 (en) 2010-12-20 2016-12-22 The Rockefeller University Modulating agonistic TNFR antibodies
WO2012109238A2 (fr) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Procédés d'augmentation des réponses immunitaires à l'aide d'agents qui se lient directement à ire-1 et activent ire-1
JP5458188B2 (ja) 2011-02-17 2014-04-02 協和発酵キリン株式会社 抗ｃｄ４０抗体の高濃度製剤
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
EP4338750A3 (fr) 2011-03-11 2024-05-15 Beth Israel Deaconess Medical Center Inc. Anticorps anti-cd40 et leurs utilisations
AU2012233652B2 (en) 2011-03-31 2017-05-18 Centre Leon Berard Antibodies directed against ICOS and uses thereof
TR201905909T4 (tr) 2011-04-19 2019-05-21 Pfizer Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları.
WO2012145493A1 (fr) 2011-04-20 2012-10-26 Amplimmune, Inc. Anticorps et autres molécules qui se lient à b7-h1 et à pd-1
MX354243B (es) 2011-04-21 2018-02-20 Bristol Myers Squibb Co Polipeptidos anticuerpos que antagonizan cd40.
JP5917498B2 (ja) 2011-04-25 2016-05-18 第一三共株式会社 抗ｂ７−ｈ３抗体
WO2012149356A2 (fr) 2011-04-29 2012-11-01 Apexigen, Inc. Anticorps anti-cd40 et leurs procédés d'utilisation
SG195082A1 (en) 2011-05-25 2013-12-30 Innate Pharma Sa Anti-kir antibodies for the treatment of inflammatory disorders
WO2013006490A2 (fr) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Anticorps se liant spécifiquement à tim3
HUE037700T2 (hu) 2011-07-11 2018-09-28 Glenmark Pharmaceuticals Sa OX40-hez kötõdõ ellenanyagok és felhasználásuk
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
JP6038920B2 (ja) 2011-08-23 2016-12-07 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗ｏｘ４０抗体およびそれを使用する方法
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
MY175224A (en) 2012-03-15 2020-06-16 Janssen Biotech Inc Human anti-cd27 antibodies, methods, and uses
WO2013152039A1 (fr) 2012-04-02 2013-10-10 The Trustees Of Columbia University In The City Of New York Composés, compositions, et procédés pour moduler la ferroptose et traiter des troubles excitotoxiques
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
CN115093480A (zh) 2012-05-31 2022-09-23 索伦托药业有限公司 与pd-l1结合的抗原结合蛋白
KR101566538B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ17 세포 전환용 에피토프 및 이의 용도
US9695133B2 (en) 2012-07-13 2017-07-04 The Trustees Of Columbia University In The City Of New York Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use
US9268936B2 (en) 2012-07-27 2016-02-23 Mandiant, Llc Physical memory forensics system and method
CN111499755A (zh) 2012-08-03 2020-08-07 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
WO2014033327A1 (fr) 2012-09-03 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps anti-icos pour le traitement de la réaction greffe contre hôte
EP2904011B1 (fr) 2012-10-02 2017-08-23 Bristol-Myers Squibb Company Combinaison d'anticorps anti-kir et d'anticorps anti-pd-1 pour le traitement du cancer
KR102237639B1 (ko) 2012-10-11 2021-04-07 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트
US9872924B2 (en) 2012-10-19 2018-01-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
EP2912063A1 (fr) 2012-10-23 2015-09-02 Bristol-Myers Squibb Company Association d'anticorps anti-kir et anti-ctla-4 pour le traitement du cancer
JP2016011258A (ja) 2012-10-26 2016-01-21 株式会社ペルセウスプロテオミクス 抗ヒトｃｄ４０モノクローナル抗体及びその利用
JPWO2014065402A1 (ja) 2012-10-26 2016-09-08 株式会社ペルセウスプロテオミクス 抗ヒトｃｄ４０モノクローナル抗体及びその利用
WO2014070934A1 (fr) 2012-10-30 2014-05-08 Apexigen, Inc. Anticorps anti-cd40 et procédés d'utilisation
MX2015007846A (es) 2012-12-19 2016-04-28 Amplimmune Inc Anticuerpos anti-b7-h4 humana y sus usos.
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
EP3299391B1 (fr) 2013-03-14 2019-12-04 Genentech, Inc. Anticorps et immunoconjugués anti-b7-h4
WO2014140374A2 (fr) 2013-03-15 2014-09-18 Novo Nordisk A/S Anticorps monovalents anti-cd27
US20140322236A1 (en) 2013-03-15 2014-10-30 Sdix, Llc Anti-human adora2a antibodies
MD20180107A2 (ro) 2013-03-18 2019-06-30 Biocerox Products B.V. Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora
US20160084839A1 (en) 2013-04-02 2016-03-24 Marisa Dolled-Filhart Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
CA2913312A1 (fr) 2013-05-24 2014-11-27 Medimmune, Llc Anticorps anti-b7-h5 et leurs utilisations
CN105683217B (zh) 2013-05-31 2019-12-10 索伦托治疗有限公司 与pd-1结合的抗原结合蛋白
NZ714765A (en) 2013-06-06 2021-12-24 Pf Medicament Anti-c10orf54 antibodies and uses thereof
WO2014209168A1 (fr) 2013-06-24 2014-12-31 Kim Ruslan Zynsonovich Communicateur automobile
GB201311487D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Bispecific molecules
BR112016001420A2 (pt) 2013-08-02 2018-01-23 Aduro Biotech Holdings Europe B V combinação de agonistas de cd27 e inibição pontual imune para estimulação imune
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
US10077305B2 (en) 2013-09-10 2018-09-18 Medimmune Limited Antibodies against PD-1 and uses thereof
WO2015051149A1 (fr) 2013-10-04 2015-04-09 The Trustees Of Columbia University In The City Of New York Analogues de sorafenib et leurs utilisations
WO2015069785A1 (fr) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Combinaison d'anticorps anti-kir et d'anticorps anti-cs1 pour traiter un myélome multiple
EP3076962A4 (fr) 2013-12-02 2017-10-18 The Trustees of Columbia University in the City of New York Modulation de la ferroptose et traitement des troubles excitotoxiques
GB201322583D0 (en) 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
PE20160753A1 (es) 2013-12-20 2016-08-01 Hoffmann La Roche Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
WO2015109009A1 (fr) 2014-01-15 2015-07-23 The Trustees Of Columbia University In The City Of New York Analogues carbonylés de l'érastine et leur utilisation
WO2015119923A1 (fr) 2014-02-04 2015-08-13 Pfizer Inc. Combinaison d'un antagoniste de pd -1 et d'un agoniste de 4-1bb pour le traitement du cancer
US10435475B2 (en) 2014-03-07 2019-10-08 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize CD40 to treat IBD
MX2016015181A (es) 2014-05-21 2017-05-25 Pfizer Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
ES2860751T3 (es) 2014-05-28 2021-10-05 Agenus Inc Anticuerpos anti-GITR y procedimientos de uso de estos
WO2015181267A1 (fr) 2014-05-29 2015-12-03 Spring Bioscience Corporation Anticorps anti-b7-h3 et leurs utilisations diagnostiques
EP3148981A4 (fr) 2014-05-30 2017-11-08 The Trustees of Columbia University in the City of New York Composés liant ras multivalents
WO2015188047A1 (fr) 2014-06-06 2015-12-10 University Of Maryland, Baltimore Anticorps monoclonaux anti-cd-137 présentant des capacités de liaison distinctes au fcγr pour le traitement d'un cancer ou d'une auto-immunité
LT3151921T (lt) 2014-06-06 2019-12-10 Bristol Myers Squibb Co Antikūnai prieš gliukokortikoidu indukuojamą naviko nekrozės faktoriaus receptorių (gitr) ir jų panaudojimas
EP3157563A1 (fr) 2014-06-23 2017-04-26 TheraMAB LLC Compositions et méthodes pour une immunothérapie efficace et sûre
US20170151388A1 (en) 2014-07-09 2017-06-01 Novo Nordisk A/S Motorized Drug Delivery Device
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
MX2017001864A (es) 2014-08-12 2017-08-02 Alligator Bioscience Ab Tratamientos conjuntos con anticuerpos anti cd40.
EP3180357B1 (fr) 2014-08-14 2019-07-03 F.Hoffmann-La Roche Ag Thérapie de combinaison d'anticorps d'activation cd40 humains et anticorps contre le récepteur humain pd-l1
WO2016028810A1 (fr) 2014-08-18 2016-02-25 Biogen Ma Inc. Anticorps anti-cd40 et leurs utilisations
EP3183269A2 (fr) 2014-08-22 2017-06-28 Bristol-Myers Squibb Company Traitement du cancer à l'aide d'une combinaison d'un anticorps anti-pd-1 et d'un anticorps anti-cd137
CN106715469B (zh) 2014-08-27 2021-10-22 纪念斯隆-凯特琳癌症中心 抗体、组合物和用途
KR102058846B1 (ko) 2014-08-29 2020-02-20 에프. 호프만-라 로슈 아게 종양-표적 il-2 변이체 면역사이토카인 및 인간 pd-l1에 대한 항체의 조합 요법
CN113698488A (zh) 2014-09-12 2021-11-26 基因泰克公司 抗-b7-h4抗体及免疫缀合物
KR20170062485A (ko) 2014-10-03 2017-06-07 다나-파버 캔서 인스티튜트 인크. 글루코코티코이드-유도 종양 괴사 인자 수용체(gitr) 항체 및 이의 사용 방법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
KR20170075778A (ko) 2014-10-27 2017-07-03 에이전시 포 사이언스, 테크놀로지 앤드 리서치 항-tim-3 항체
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
ES2772307T3 (es) 2014-10-28 2020-07-07 Childrens Univ Hospital Tuebingen Tratamiento de pacientes pediátricos con LLA-PCB con un anticuerpo anti-kir
EP3212230B1 (fr) 2014-10-29 2021-01-20 Seagen Inc. Dosage et administration des anticorps anti-cd40 non fucosylés
WO2016070001A1 (fr) 2014-10-31 2016-05-06 Jounce Therapeutics, Inc. Méthodes de traitement d'états pathologiques avec des anticorps qui se lient à b7-h4
TWI618717B (zh) 2014-11-06 2018-03-21 赫孚孟拉羅股份公司 抗ｔｉｍ３抗體及使用方法
US10766959B2 (en) 2014-12-11 2020-09-08 Pierre Fabre Medicament Anti-C10ORF54 antibodies and uses thereof
US9963509B2 (en) 2014-12-23 2018-05-08 Full Spectrum Genetics, Inc. Anti-B7H3 binding compounds and uses thereof
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
WO2017058716A1 (fr) 2015-09-28 2017-04-06 Vivace Therapeutics, Inc. Composés tricycliques
WO2018118711A1 (fr) * 2016-12-19 2018-06-28 The Trustees Of Columbia University In The City Of New York Inducteurs de ferroptose à petites molécules
CN108409737B (zh) * 2017-02-10 2020-07-03 华东理工大学 4-甲氧基苯基取代四氢-β-咔啉哌嗪二酮类衍生物及其应用
WO2018218087A1 (fr) * 2017-05-24 2018-11-29 K-Gen, Inc. Méthodes de traitement du cancer
US20200163966A1 (en) * 2017-06-28 2020-05-28 The Regents Of The University Of California Methods and compositions for treating melanoma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017120445A1 (fr) * 2016-01-07 2017-07-13 The Broad Institute, Inc. Composés et des méthodes pour augmenter l'infiltration tumorale par des cellules immunitaires

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JENNIFER TSOI等: "Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress", 《CANCER CELL》, vol. 33, no. 5, pages 890 - 904 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113421613A (zh) * 2021-06-08 2021-09-21 吴安华 一种基于铁死亡水平评价胶质母细胞瘤患者免疫治疗反应性的系统及分析方法
CN113421613B (zh) * 2021-06-08 2024-06-18 吴安华 一种基于铁死亡水平评价胶质母细胞瘤患者免疫治疗反应性的系统及分析方法
CN117625547A (zh) * 2022-08-25 2024-03-01 广州百吉生物制药有限公司 联合表达gpx4的新一代嵌合抗原受体及其应用
CN115804772A (zh) * 2022-11-16 2023-03-17 山东大学 一种铁死亡抑制剂在抗病毒感染中的应用
CN115804772B (zh) * 2022-11-16 2024-04-26 山东大学 一种铁死亡抑制剂在抗病毒感染中的应用

Also Published As

Publication number Publication date
JP2021528393A (ja) 2021-10-21
WO2019241730A8 (fr) 2020-02-06
US20210251994A1 (en) 2021-08-19
KR20210035805A (ko) 2021-04-01
WO2019241730A2 (fr) 2019-12-19
WO2019241730A3 (fr) 2020-03-12
MA52889A (fr) 2021-04-21
AU2019287765A1 (en) 2021-01-07
CA3103629A1 (fr) 2019-12-19
EP3806848A2 (fr) 2021-04-21

Similar Documents

Publication Publication Date Title
US11376272B2 (en) Methods of modulating immune activity
Hossain et al. Reinvigorating exhausted CD8+ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy
CN112638375A (zh) 通过后细胞信号传导因子的调节来增加免疫活性
Svanberg et al. Targeting the tumor microenvironment in chronic lymphocytic leukemia
CA2965034C (fr) Combinaison d'un agent immunomodulaire et d'un oligonucleotide antisens
EP3008173B1 (fr) Procédés et compositions pour réduire l'immunodépression par des cellules tumorales
JP2020164539A (ja) 腫瘍免疫寛容を破綻させるためのｙａｐの阻害方法
JP2018514576A (ja) 治療のためのｃｄ３０×ｃｄ１６抗体とｐｄ−１アンタゴニストとの組み合わせ
US20230114107A1 (en) Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
JP2022512161A (ja) 免疫療法のための組成物及び方法
JP2023532339A (ja) サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
KR20240026507A (ko) 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
Muik et al. DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity
JP2018524588A (ja) 骨髄由来サプレッサー細胞中のテトラスパニン３３（Ｔｓｐａｎ３３）を標的化するがん療法
CN112105368A (zh) 组蛋白修饰剂将效应t细胞重编程的用途
JP2024112878A (ja) Ｔ細胞による認識を強化するよう抗原性を調節する方法
JP7492752B2 (ja) 免疫療法のためのアジュバントとしてのグアナベンズ
US20210380942A1 (en) Methods and compositions for the treatment of cancer and infectious diseases
CA3218832A1 (fr) Polytherapie utilisant un anticorps anti-cd300c
Lotze et al. CD28 co-stimulation: novel insights and applications in cancer immunotherapy
Ratna et al. Immune Checkpoints are Important Therapeutic Targets in Cancer Immunotherapy
WO2022265864A9 (fr) Modulateurs de tim-3 modulant l'immunité anti-tumorale par régulation de l'activation de l'inflammation
WO2024102874A1 (fr) Le fénofibrate améliore les thérapies par lymphocytes t
WO2023083868A1 (fr) Agoniste de tlr7 et combinaisons pour le traitement du cancer
WO2022056043A1 (fr) Immunoconjugués cpg de thérapie anti-cancéreuse

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination